Abstract
Background and Aims: Obeticholic acid (OCA) is the farnesoid X receptor (FXR) agonists and expected as a therapeutic medicine of non-alcoholic steatohepatitis (NASH) because it inhibits lipid and bile acid synthesis. FXR is activated by bile acids and expresses in various tissues. Activation of macrophage-FXR is reported to suppress the expression of CD36 in macrophages. CD36 is a scavenger receptor which is important for phagocytosis of oxidized LDL. We investigated whether OCA ameliorates NASH and atherosclerosis using SHRSP5/Dmcr rats.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
